Medpace (MEDP) stock surged on Tuesday after the drug and medical device development company released its Q2 2025 earnings report. Diluted earnings per share of $3.10 surpassed Wall Street’s estimate of $2.98. The company’s EPS also increased 12.73% year-over-year from $2.75.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Medpace’s revenue for Q2 2025 came in at $603.31 million, which was well above analysts’ estimate of $538.77 million. It also rose 14.2% year-over-year from $528.1 million. This represented a backlog conversion rate of 21.2%.
Additionally, Medpace raised its outlook for 2025 in its latest earnings report. The company expects diluted EPS to range from $13.76 to $14.53 alongside revenue between $2.42 billion and $2.52 billion. Wall Street’s estimate for 2025 includes diluted EPS of $12.94 on revenue of $2.18 billion.
Medpace Stock Movement Today
Medpace stock was up 44.39% in pre-market trading on Tuesday, following a 0.96% drop yesterday. The stock was down 7.03% year-to-date and has fallen 13.55% over the past 12 months.
Is Medpace Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Medpace is Hold, based on six Hold ratings over the past three months. With that comes an average MEDP stock price target of $300.20, representing a potential 2.81% downside for the shares. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report.
